Amicus Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021
Amicus Therapeutics (Nasdaq: FOLD) will host a conference call and live audio webcast on August 5, 2021, at 8:30 a.m. ET to discuss its financial results for Q2 2021, ended June 30, 2021. Investors can join the call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international) with conference ID 7374935. A live audio webcast will be available on the company’s website. A replay will be accessible for seven days starting at 11:30 a.m. ET, with specific access numbers for both U.S./Canada and international participants.
- None.
- None.
PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2021.
Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 7374935. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
A replay of the call will be available for seven days beginning at 11:30 a.m. ET. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 7374935.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACT:
Investors:
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
When will Amicus Therapeutics announce Q2 2021 earnings results?
How can I join the Amicus Therapeutics earnings call?
Is there a way to access the Amicus Therapeutics earnings call replay?
Where can I find the webcast for the Amicus Therapeutics earnings call?
